Balaxi Pharmaceuticals Limited · NSE:BALAXI
Balaxi Pharmaceuticals — Q4 FY2021 Earnings Presentation
48 slides from Balaxi Pharmaceuticals's earnings presentation, May 26, 2021
Slide 1: Cover letter to National Stock Exchange
Balaxi Pharmaceuticals Limited To 26t May, 2021 Listing Department, National Stock Exchange of India Limited Exchange Plaza, Plot No C/1, G Block, BKC, Bandra (E), Mumbai-400051 Stock Code: BALAXI Sub: Investor Presentation Dear Sir/Madam, We hereby attach the Investor Presentation issued by the Com
Slide 2: Investor Presentation
Page - 01 B A L A X I P H A R M A C E U T I C A LS L I M I T E D INVESTOR PRESENTATION
Slide 3: Disclaimer
Page - 02 B A L A X I P H A R M A C E U T I C A LS L I M I T E D Disclaimer This presentation and the following discussion may contain “forward-looking statements” by “Balaxi Pharmaceuticals Limited” that are not historical in nature. Such forward-looking statements are subject to certain risks and
Slide 4: Q4 & FY21 Result Highlights
Page - 03 » Q4 & FY21 Result Highlights » Business Strategy » Industry & Outlook » Business Overview » Financial Highlights INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION Q4 & FY21 RESULT HIGHLIGHTS
Slide 5: Q4 & FY21: Quick Overview
Page - 04 Q4 & FY21: Quick Overview Revenue EBITDA PAT Q4FY21 - 530 Mn Q4FY21 - 100 Mn Q4FY21 - 84 Mn FY21 – 2,313 Mn FY21 - 424 Mn FY21 - 381 Mn Q4FY21 - 25:75 Pharmaceuticals Business Pharmaceuticals Business FY21 - 25:75 contributes 58% of Revenue contributes 73% of EBITDA (Branded:Generics) 119
Slide 6: Consolidated Financial Highlights
Page - 05 Q4 & FY21: Consolidated Financial Highlights In INR Mn Revenue EBITDA & EBITDA Margin PAT & PAT Margin 2,313 18.9% 424 18.3% 15.8% 381 16.5% 530 100 84 Q4 FY21 FY21 Q4 FY21 FY21 Q4 FY21 FY21 The Company recorded a drop in revenue from INR 660 million in Q3FY21 to INR 530 million in Q4F2, t
Slide 7: Consolidated Profit and Loss Statement
Page - 06 Consolidated Profit and Loss Statement Particulars (In INR Mn) Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 FY21 Revenue From Operations 521 603 660 530 2,313 Other Income 15 16 7 -3 22 Total Income 536 619 667 527 2,336 COGS 392 455 495 378 1,721 Gross Profit 128 148 165 151 592 Gross Margin % 24.6% 2
Slide 8: Consolidated Balance Sheet
Page - 07 Consolidated Balance Sheet Particulars (In INR Mn) FY21 Particulars (In INR Mn) FY21 Shareholder's Funds 650 Non-Current Assets 59 Equity Share Capital 100 Fixed Assets – Tangible & Intangible 24 Reserves & Surplus 550 CWIP & Intangibles under development - Minority Interest - Other Non Cu
Slide 9: Segment Revenue Breakup
Page - 08 Segment Revenue Breakup Revenue Mix % (Q4FY21) Revenue Mix % (FY21) 25% 29% 58% 59% 18% 13% Pharmaceuticals Branded Consumer Products Ancillary Pharmaceuticals Branded Consumer Products Ancillary
Slide 10: Business Segment Financial Highlights
Page - 09 Q4 & FY21: Business Segment Financial Highlights In INR Mn Revenue Gross Profit Gross Profit Margin 1361 430 36% 32% 660 19% 19% 17% 18% 305 292 109 110 130 95 51 24 18 Q4FY21 FY21 Q4FY21 FY21 Q4FY21 FY21 Pharmaceuticals Pharmaceuticals Pharmaceuticals Ancillary Ancillary Ancillary Branded
Slide 11: Company Overview
Page - 12 Section Starts as Page - 12 » Q4 & FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION COMPANY OVERVIEW
Slide 12: Vision and Mission
Page - 13 Balaxi Pharmaceuticals: Bridging the supply chain gap in frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D We are a branded IPR-based pharmaceuticals Company focusing on frontier markets, with a vast and growing portfolio of drugs across multiple therapeutic segments.
Slide 13: Values and Purpose
Page - 14 Balaxi Pharmaceuticals: Bridging the supply chain gap in the frontier markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D Our value system is the foundation for transparency and strong corporate governance. While we create value for shareowners, we work ethically and honestly to
Slide 14: Global Presence With Localisation
Page - 15 Balaxi Pharmaceuticals: Global Presence With Localisation B A L A X I P H A R M A C E U T I C A LS L I M I T E D A growing pharmaceuticals company with on-ground presence in markets within Africa, Caribbean Islands & Latin America Headquartered in Hyderabad, India, we are an IPR-driven ass
Slide 15: The Company's Evolution
Page - 16 Our Genesis: The Company’s Evolution B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pre 2017 » The Company was listed on NSE in 2015 as ‘The Anandam Rubber Company Ltd’ 2017-2019 » In March, 2017, the Company was taken over by Balaxi Group, a prominent pharmaceuticals player in Ang
Slide 16: Balaxi Group's Journey
Page - 17 Our Genesis: Balaxi Group’s Journey B A L A X I P H A R M A C E U T I C A LS L I M I T E D 2003-07 2008-10 2011-13 2014-16 2017-19 2020-2021 » Commenced » Created front-end » Started sourcing » In 2014, the Group » Setup central » Submitted several Pharmaceuticals presence for its pharmace
Slide 17: Business Strategy
Page - 18 » Q4 & FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION BUSINESS STRATEGY
Slide 18: Our Approach For Creating Value
Page - 19 How We Operate: Our Approach For Creating Value B A L A X I P H A R M A C E U T I C A LS L I M I T E D 1 2 3 4 5 6 Intellectual Robust Product Asset-Light Geographical Focus on Brand Property Infrastructure & Registrations Production Footprint Equity Research Logistics » Balaxi undertakes
Slide 19: Straddling The Value Chain
Page - 20 How We Operate: Straddling The Value Chain B A L A X I P H A R M A C E U T I C A LS L I M I T E D Market & Product Selection We focus on bringing essential medicines within the reach of populations within frontier markets, which are challenging Market Research to penetrate. In particular,
Slide 20: Our Strengths Built Over Time
Page - 21 Balaxi’s Key Differentiators: Our Strengths “Built Over Time” B A L A X I P H A R M A C E U T I C A LS L I M I T E D Four ‘E’s differentiates BALAXI 1 Experience Two Decades of versatile experience of the BALAXI group ensures flawless execution. 19 years Entry into The Company enters a par
Slide 21: The Making of a Pharmaceuticals Major in Frontier Markets
Page - 22 Investing In Balaxi: The making of a Pharmaceuticals Major in multiple Frontier Markets B A L A X I P H A R M A C E U T I C A LS L I M I T E D » The Company participates in all stages of the pharma value chain, except in the R&D and manufacturing stages. Instead, it prefers to register pro
Slide 22: The Making of a Pharmaceuticals Major (contd.)
Page - 23 Investing In Balaxi: The making of a Pharmaceuticals Major in multiple Frontier Markets (contd.) B A L A X I P H A R M A C E U T I C A LS L I M I T E D 3 » The focus on the Company’s ‘cash & carry’ » The Company presently operates in three main regions Angola, Dominican model ensures regul
Slide 23: An Asset-Light Business Model Focussed on IPRs
Page - 24 Balaxi Pharmaceuticals: An Asset-Light Business Model Focussed on IPR’s B A L A X I P H A R M A C E U T I C A LS L I M I T E D Pharmaceuticals Industry Value Chain Balaxi’s Operating Areas Research & Drug Market Product Market & Pharmacy Registrations Manufacturing Development Discovery Re
Slide 24: Pharmaceuticals Business Overview
Page - 25 Pharmaceuticals Business Overview B A L A X I P H A R M A C E U T I C A LS L I M I T E D 37% are Anitbiotic » The Company has a healthy ratio of branded and generic medicines in its portfolio of 25:75 (Branded: Generics). » The Company is in the business of supplying everyday medicines add
Slide 25: Inherent Strategy Built Over Time Leading To Strong Brand Presence
Page - 26 Pharma Product Portfolio: Inherent Strategy Built Over Time Leading To Strong Brand Presence Geographical Mix % (Q4FY21) Geographical Mix % (FY21) • The Company generates 77% of the pharmaceuticals revenue from Angola followed Dominican Republic and Guatemala. 9% 7% • The product split bet
Slide 26: Product Mix & Categories as of FY21 - 1/2
Page - 27 Pharma Product Portfolio: Product Mix & Categories as of FY21 - 1/2 Product Mix % (Angola) Product Mix % (Guatemala) Product Mix % (Dominican Republic) 19% 14% 33% 67% 81% 86% Branded Generics Branded Generics Branded Generics Product Category Mix % (Angola) Product Category Mix % (Guatema
Slide 27: Product Mix & Categories as of FY21 - 2/2
Page - 28 Pharma Product Portfolio: Product Mix & Categories as of FY21 - 2/2 Therapeutic Area % (Angola) Therapeutic Area % (Guatemala) Therapeutic Area % (Dominican Republic) 26% 30% 38% 36% 40% 60% 14% 17% 15% 24% Antibiotics Analgesic Anti Malaria Others Antibiotics Analgesic Others Antibiotics
Slide 28: Our Offerings - 300+ products across Therapeutic Areas
2 Page - 29 9 Pharma Product Portfolio: Our Offerings- 300+ products across multiple Therapeutic Areas
Slide 29: Glimpse of Our Products
Page - 30 Glimpse of Our Products B A L A X I P H A R M A C E U T I C A LS L I M I T E D
Slide 30: Glimpse of our Products - Branded Consumer Products
Page - 31 Glimpse of our Products- Branded Consumer Products
Slide 31: Adding New Geographies and Extensive Presence Through On-Ground Infrastructure
Page - 32 “Our Land & Expand Strategy”: Adding New Geographies and Extensive Presence Through Robust B A L A X I P H A R M A C E U T I C A LS L I M I T E D On-Ground Infrastructure Our current established markets are Angola, Guatemala and Dominican Republic, where we have a strong presence in terms
Slide 32: Balaxi Pharmaceuticals Group Structure
Page - 33 Balaxi Pharmaceuticals Group Structure B A L A X I P H A R M A C E U T I C A LS L I M I T E D Balaxi Pharmaceuticals Limited YAP, Sociedade Unipessola Balaxi Mozambique Global DMCC, LDA Dubai (WOS) (WOS) Balaxi Balaxi Balaxi Balaxi Balaxi Balaxi YAP, Balaxi Balaxi Balaxi Healthcare Healthc
Slide 33: Industry & Outlook
Page - 34 » Q4 & FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION INDUSTRY & OUTLOOK
Slide 34: Macro Economy & Industry Data
Page - 35 New Geographies: Macro Economy & Industry Data Macro Economic Data as on 2020 • Central American countries reported US$ 2,625 million of pharmaceuticals S&P Credit GDP Per imports between January to September 2020. GDP * GDP Population Inflation Country Rating Capita * (US$ bn) Growth % (m
Slide 35: Enter, Expand and Excel
Page - 36 Future Roadmap: Enter, Expand and Excel B A L A X I P H A R M A C E U T I C A LS L I M I T E D The Company aims to establish its presence and expand in 20 frontier markets over the next 5 years. Balaxi In 2021-22 - Balaxi In 2020 Expansion In New – Business Geographies. Balaxi In 2023 & Co
Slide 36: Robust Pipeline Ahead
Page - 37 Pharma Products Registrations*: Robust Pipeline Ahead Submitted to Ministry Existing Registrations* of Health (MOH) Pipeline Guatemela 63 Guatemela 85 Honduras El Salvador 83 60 Dominician Central African Republic Nicaragura Dominican El Salvador Honduras Honduras 30 Republic 26 Mozambique
Slide 37: Business Overview
Page - 38 » Q4 & FY21 Result Highlights » Company Overview » Business Strategy » Industry & Outlook » Business Overview INVESTOR B A L A X I P H A R M A C E U T I C A LS L I M I T E D PRESENTATION BUSINESS OVERVIEW
Slide 38: Leading Supplier Of Formulations in Angola, Guatemala and Dominican Republic
Page - 39 Pharmaceuticals Business: Leading Supplier Of Formulations in Angola, Guatemala and B A L A X I P H A R M A C E U T I C A LS L I M I T E D Dominican Republic An IPR-driven pharma company with an asset-light, stock & sell model supplying branded & generic medicines in frontier markets. Ango
Slide 39: Leading Pharmaceuticals Player in Angola
Page - 40 Pharmaceuticals Business: Leading Pharmaceuticals Player in Angola Industry Snapshot • Angola is the second largest oil producer in Africa with a population of ~32 million in 2019. • The GDP per capita is US$2,012.15 in 2020. • Angola witnessed pharmaceuticals imports worth US$ 351 million
Slide 40: Leading Pharmaceuticals Player in Guatemala
Page - 41 Pharmaceuticals Business: Leading Pharmaceuticals Player in Guatemala Industry Snapshot • Guatemala is part of the Latin American-Dominican Republic Free Trade Agreement (CAFTA-DR) which includes the United States and 6 Latin American countries. • Guatemala witnessed pharmaceutical imports
Slide 41: Leading Pharmaceuticals Player in Dominican Republic
Page - 42 Pharmaceuticals Business: Leading Pharmaceuticals Player in Dominican Republic Industry Snapshot • Dominican Republic is part of the Central American-Dominican Republic Free Trade Agreement (CAFTA- DR) which includes the United States and 6 Central American countries. • Dominican Republic
Slide 42: Ancillary Business: Encashing Our On-Ground Infrastructure
Page - 43 Ancillary Business: Encashing Our On-Ground Infrastructure Industry Snapshot • Angolan real estate market is largely dependent on state investments. • Property market continues to be seen as a safe-haven investment in the face of currency devaluation. • Builder’s Hardware is import depende
Slide 43: Branded Consumer Products: An Emerging Business
Page - 44 Branded Consumer Products: An Emerging Business Industry Snapshot • Angola is one of the most promising consumer-goods market in Africa. • Angola imports most of its consumer goods and utilities from countries such as Portugal, Brazil, China and South Africa • According to Research & Marke
Slide 44: Leadership Team
Page - 45 Strong Management: Leadership Team B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ashish Maheshwari Pranav Maheshwari Paridhi Maheshwari Chairman & Managing Director Head – Latin America Head – Branded Consumer Products Founder of the company BBA and Economics Graduate from Emory B
Slide 45: Leadership Team
Page - 46 Strong Management: Leadership Team B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ram Chawla Amol Mantri Country Head – Angola CFO Associated with the Balaxi Group since 2009 Qualified Chartered Accountant and Certified Public Accountant from USA Inherently talented in person to pe
Slide 46: Board of Directors
Page - 47 Strong Governance: Board of Directors B A L A X I P H A R M A C E U T I C A LS L I M I T E D Ashish Maheshwari Minoshi Maheshwari Chairman & Managing Director Non-Executive Director Founder of the company Co-Founder of the company First generation entrepreneur and a qualified A commerce gr
Slide 47: Board of Directors
Page - 48 Strong Governance: Board of Directors B A L A X I P H A R M A C E U T I C A LS L I M I T E D Kunal Bhakta Gandhi Gamji M.S Rao Purnima Singh Kamble Independent Director Independent Director Independent Director Independent Director A Chartered Accountant with 15 years of MBA and BE in Engi
Slide 48: Thank You
THANK YOU! B A L A X I P H A R M A C E U T I C A LS L I M I T E D Balaxi Pharmaceuticals Limited Chinta Shalini Compliance Officer Email: secretarial@balaxi.in IR Consultants Dikshita Jain / Chintan Mehta IR Consultants - Dickenson World Contact No: +91 90224 87957/ 98921 83389 Email: balaxi@dickens
Balaxi Pharmaceuticals — Q4 FY2021 Earnings Presentation on 6ix